Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ABT - Abbott Labs -- Ignore unavailable to you. Want to Upgrade?

To: John McCarthy who wrote (282)	6/19/2000 9:43:00 AM
From: Skywatcher	Respond to of 328

Hill-Rom Company, a Hillenbrand Industries Company Inc., Announces New E-CommerceInitiative Agreement with Global Healthcare Exchange, LLC will Improve Customer Service and Grow Market Reach BATESVILLE, Ind., June 19 /PRNewswire/ -- Hill-Rom Company Inc., a Hillenbrand Industries Inc. (NYSE: HB - news) company, announced today it will join the Global Healthcare Exchange, LLC (the Exchange) a healthcare business-to- business consortium formed to streamline the hospital-supply business and promote a global, customer-driven on-line marketplace for goods and services. The Exchange is an independent on-line enterprise that will facilitate the exchange of information between suppliers and customers related to buying, selling and distributing medical equipment devices and health care products and services over the Internet worldwide. ``The power and far reaching capabilities of the Internet, coupled with Hill-Rom's world-class sales and service organization, will allow us to serve new markets that were restricted by geographic constraints. More importantly, Hill-Rom's new and existing customers will have speedier, enhanced service; broader access to products; and, ease-of-use and account information based on their individual needs,'' said Bob Tennison, Hill-Rom president and CEO. ``Through the Exchange, Hill-Rom will strengthen our interaction with customers, group purchasing organizations in the United States, and overseas distributors.'' Five major U.S.-based global healthcare companies launched the Exchange in March: Johnson & Johnson (NYSE: JNJ - news), General Electric Co.'s GE Medical Systems unit (GE), Baxter International Inc. (NYSE: BAX - news), Abbott Laboratories (NYSE: ABT - news), and Medtronic Inc. (NYSE:MDT - news). Hill-Rom joins the launch of the preliminary phase, which will focus on the United States and is expected in the third quarter this year. The Exchange is expected to reach a global magnitude by 2001. Tennison said joining the Exchange is just one of Hill-Rom's ongoing eBusiness initiatives. Hill-Rom will continue to apply Internet technologies to all business processes, especially in customer service and business growth areas. ``Freeing our award-winning sales and service associates from routine paperwork allows them time to do what they do best: interact and serve our customers on a one-to-one basis. They will be better suited to focus on new and existing customer relationships and providing solutions to our customers' needs,'' Tennison said. This agreement exemplifies Hillenbrand Industries' concentric growth strategy and illustrates how it intends to add customer and shareholder value by growing new and existing markets. Chris

To: John McCarthy who wrote (282)	6/29/2000 10:18:00 AM
From: Skywatcher	Respond to of 328

Abbott Laboratories and Battelle Pulmonary Therapeutics Announce License Agreement ABBOTT PARK, Ill., June 29 /PRNewswire/ -- Abbott Laboratories, Ross Products Division and Battelle Pulmonary Therapeutics, Inc. (BPT), announced today an agreement under which BPT will license to Abbott new products and drug delivery technology to develop therapies for a variety of respiratory diseases. ``Battelle and Abbott have had a long, successful history in the development of proprietary devices for the delivery of nutritional products,'' said Joy Amundson, senior vice president, Ross Products Division. ``We look forward to expanding this relationship into the area of pharmaceutical products for respiratory diseases.'' ``We are very encouraged by this business relationship and the laboratory work we have done so far on new pulmonary therapies,'' said Dennis Cearlock, president and chief executive officer, Battelle Pulmonary Therapeutics, a subsidiary of Battelle Memorial Institute. ``Abbott has formulation and manufacturing expertise in proprietary respiratory disease compounds and BPT has expertise in drug delivery device technology. The collaboration between the two companies' research groups will provide a critical mass to develop new therapies together and move forward with clinical development.'' Looking good here and nice to see it over 43...whew. chris

To: John McCarthy who wrote (282)	7/5/2000 1:20:01 PM
From: Skywatcher	Respond to of 328

Abbott in cancer drug licensing deal with Eisai NORTH CHICAGO, Ill., July 5 (Reuters) - Pharmaceutical company Abbott Laboratories Inc. (NYSE:ABT - news) and Eisai Co. Ltd. of Japan signed a licensing deal for Abbott to market the Phase 1 development-stage cancer treatment compound E7010, the companies said on Wednesday. Financial terms were not disclosed, but under the agreement Abbott will have worldwide marketing and development rights for the compound, except in Japan and Asia where Eisai will maintain exclusive rights. ``This agreement advances Abbott's oncology pipeline by adding another promising compound that is currently in development,'' said Arthur Higgins, president of Abbott's Pharmaceutical Products Division, said in a statement. ``We have identified oncology as one of our key therapeutic franchises, placing a significant focus on research and development in this area. The addition of this compound will enable us to enhance our pipeline and potential product offerings in the future,'' he said. E7010 is an oral medication with that stops cell reproduction with fewer side effects than current chemotherapy treatments. Preliminary data from Phase I clinical trials of E7010 indicate promising efficacy and tolerability, Abbott said. The agreement will include milestone payments and royalties related to the development and sales of the compound. Eisai Co is a research-based human health care company which discovers, develops and markets products in more than 30 countries. Looking GOOD chris